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Disseminated toxoplasmosis in a heart transplant patient 
despite co-trimoxazole prophylaxis: A case report
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We report the case of a 61 year-old male who underwent heart transplantation eight months before 
developing a systemic condition with central nervous system, lung, kidney, colonic, cutaneous, and 
hematologic involvement, found to be secondary to a systemic toxoplasmosis despite co-trimoxazole 
prophylaxis in a previous-to-transplant seronegative patient receiving a heart from a seropositive donor. 
A review of prophylactic options in our environment is discussed.
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Toxoplasmosis diseminada en un paciente con trasplante de corazón a pesar de la profilaxis 
con trimetoprim-sulfametoxazol
Se reporta el caso de un paciente de sexo masculino, de 61 años de edad, quien ocho meses después 
de someterse a un trasplante de corazón presentó una enfermedad sistémica con compromiso del 
sistema nervioso central y del sistema inmunológico, así como de pulmón, riñón, colon y piel, y a 
quien finalmente se le diagnosticó toxoplasmosis diseminada, a pesar de haber recibido profilaxis con 
trimetoprim-sulfametoxazol, debido a que el órgano provenía de un donante positivo para toxoplasmosis 
siendo él un receptor negativo. Se discuten las opciones de profilaxis en nuestro medio.
Palabras clave: toxoplasmosis; trasplante de corazón; tolerancia inmunológica; seroconversión. 
doi: https://doi.org/10.7705/biomedica.v34i2.3189
Toxoplasmosis is an infection caused by the proto-
zoon Toxoplasma gondii. It is prevalent worldwide, 
affecting approximately one third of the world’s 
population (1). Seroprevalence increases with age 
and there is no gender difference.
Toxoplasmosis is transmitted via oral intake of food 
contaminated with the parasite’s cysts or oocysts. 
However, there are reports of transmission through 
transplanted organs and blood transfusions, as 
well as vertical transmission (2). 
It evolves to a systemic disease, and only 10% of 
the affected population is symptomatic. The clinical 
course is usually benign, but it can be lethal, especially 
in immunosuppressed patients (3). Systemic clinical 
signs include generalized adenopathies, myocar-
ditis, polymyositis, pneumonitis, encephalitis and 
chorioretinitis. Skin manifestations are rare, though 
usually present in immunosuppressed patients. 
Given the great variability in the appearance of 
cutaneous toxoplasmosis, histopathological studies 
are required for diagnosis.
Although direct observation of the parasite is 
possible in most tissue samples, diagnosis should 
be confirmed by immunohistochemistry and poly-
merase chain reaction (PCR) (4). 
Medical therapy is indicated when there is active 
skin or ocular infection, or congenital disease, and 
in all immunosuppressed patients. Sulfadiazine in 
combination with pyrimethamine is the treatment 
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of choice. Seronegative heart transplant patients 
should receive prophylaxis with pyrimethamine and 
sulfadiazine for the first three months followed by 
co-trimoxazole for the rest of their lives (5,6).
Case report
We report the case of a 61-year-old male patient 
with a past medical history of hypertension, 
dyslipidemia, hypothyroidism, heart failure with 
preserved ejection fraction and severe coronary 
artery disease, in whom surgical and percutaneous 
revascularization were performed. After surgery, 
the patient developed refractory angina despite 
optimal anti-ischemic medication which led to 
heart transplantation. Laboratory tests previous to 
transplant were discordant for T. gondii and human 
herpes viruses type I and II. The donor had positive 
immunoglobulin M (IgM), negative immunoglobulin 
G (IgG) for T. gondii, and positive IgG for herpes 
viruses (HV) type I and type II. The receptor was 
negative for both.
After eight months of transplant the patient was 
admitted with persistent diarrhea lasting 20 days, 
abdominal pain and malaise. The immunosuppres-
sion regimen included mycophenolate mofetil, 1 g 
every 12 hours, prednisolone, 5 mg per day, and 
cyclosporine, 150 mg every 12 hours. Prophylaxis 
with co-trimoxazole, 160/800 mg per day, was 
also given.
On physical examination the patient presented with 
tachycardia, normal blood pressure and respiratory 
rate, and no fever was documented. Vesicular lesions 
with clear content and erythematous base with der-
matome distribution were seen in the right gluteus. 
Initial laboratory tests showed anemia, leukopenia 
with lymphopenia, renal dysfunction and a positive 
Tzank test (table 1). Viral load for cytomegalovirus 
(CMV) was positive with 404.000 copies/ml; therapy 
with ganciclovir, 5 mg/kg every 12 hours, was 
started with initial improvement of the diarrhea. 
However, two weeks later the patient persisted 
with leukopenia, the anemia worsened requiring 
red blood cell (RBC) transfusion and he developed 
fever as high as 39.8º C. The only additional finding 
was four 5 mm to 1 cm erythematous, mildly painful 
lesions, some in legs and thighs with white scaling 
in the center, and a similar lesion in the upper right 
eyelid (figure 1). The diarrhea reappeared, renal 
dysfunction worsened, as well as the complete 
blood count (CBC), now with pancytopenia (anemia, 
leukopenia, lymphocytopenia, neutropenia and 
thrombocytopenia). 
Empirical therapy with anidulafungin plus cefepime 
was started for febrile neutropenia. Toxoplasma 
antibody seroconversion was documented. Therapy 
with clindamycin plus pyrimethamine was started 
and the skin lesions were biopsied.
Table 1. Diagnostic aids
Laboratory tests on admission Creatinine 2.7 mg/dl, BUN 53 mg/dl
CBC (leucocytes 3100, PMN 83%, lymphocytes 13%, hemoglobin 9.4, platelet count 250.000)
AST 37 ALT 30 FA 80 TB 0.4 DB 0.3
Normal urinalysis




Negative blood cultures for fungus, bacteria, and mycobacteria
Serological and molecular 
tests
Day 5-30
Latex agglutination test negative for Cryptococcus neoformans
Hystoplasma capsulatum urinary antigen: Negative
Serum galactomannan: Negative (Platelia)
Serum CMV viral load: 404.000 copies/ml
Histopathology
Day 20
Colonoscopy: Active chronic inflammation with erosive component. Negative histochemistry 
colorations
Bone marrow biopsy: Hypocellular hematopoietic bone marrow without granuloma orcytophatic 




Normal IgA, IgE, and IgM levels. Low IgG levels (593 mg/dl N: 700.6-1600 mg/dl).
CSF studies: PCR for CMV, Epstein-Barr virus (EBV) and mycobacteria were negative. PCR for 
Toxoplasma was positive
Low serum ADAMS-13 levels
Laboratory tests on discharge Creatinine 1.4 mg/dl, BUN 24 mg/dl
CBC (leucocytes 5.300, PMN 75%, lymphocytes 20%, hemoglobin 9.4, platelet count 229.000)
PCR for Toxoplasma was positive.
BUN: Blood urea nitrogen; PMN: Polymorphonuclear; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AP: Alkalin phosphatase; 
TB: Total bilirubin; DB: Direct bilirubin
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Histopathology of skin lesions was positive and 
immunohistochemistry for toxoplasmosis confirmed 
the presence of the parasite (figures 2 and 3). 
Molecular studies with blood and cerebrospinal 
fluid (CSF) PCR were also positive for Toxoplasma 
(7). Central nervous system magnetic resonance 
(MR) did not show focal lesions.
The initial course was unfavorable, the patient 
persisted with fever, headache, encephalopathy, 
oliguric renal failure, hepatitis, pancytopenia, 
metabolic acidosis and increased lactate dehydro-
genase (LDH) up to 2.500 IU/L. Pulmonary patchy 
infiltrates were found. He was admitted to the inten-
sive care unit for mechanical ventilation. Plasma 
exchange was started for suspected thrombotic 
thrombocytopenic purpura.
After a few days the patient´s status improved, 
especially renal function and blood counts, but 
he persisted with hypogammaglobulinemia. CMV 
infection relapsed with poor response to ganciclovir. 
Gammaglobulin, 30 g intravenous (IV) weekly, was 
started with complete remission. 
He was released after six weeks of therapy with 
clindamycin and pyrimethamine upon suspicion of 
co-trimoxazole resistance. Suppression with co-
trimoxazole plus valganciclovir and gammaglobulin 
was maintained and the patient has been symptom-
free for 28 months.
Discussion
This is a heart transplant patient who developed 
systemic toxoplasmosis with central nervous system, 
pulmonary, renal, colonic, cutaneous, and hema-
tologic compromise secondary to disseminated 
toxoplasmosis. Toxoplasma gondii infection after 
heart transplant is often a severe disease. The 
clinical presentation ranges from chorioretinitis to 
disseminated infection (pulmonary, myocardial, 
hepatic and CNS infection) (8).
Toxoplasmosis in immunocompromised patients 
is usually secondary to a reactivation of latent 
infection from the donor (9). In this case, previous to 
transplantation the donor´s toxoplasmosis serology 
was discordant with the recipient´s. Toxoplasma 
cysts may persist in the donor’s myocardium, thus, 
hosts are at higher risk of developing the disease. 
With immunosuppression, the bradyzoites become 
tachyzoites, quickly proliferating and consequently 
destroying cells. 
Before the use of prophylaxis with co-trimoxazole 
there was a higher risk of disseminated toxo-
plasmosis (10). Studies of seronegative heart 
Figure 3. Special immunohistochemical staining for toxoplasma 
from the skin biopsy showing a pseudocyst. Toxoplasma RB-
9423-P rabbit monoclonal antibodies (Thermo®) were used.
Figure 2. Skin histology from the lower limb showing T. gondii 
tachyzoites forming a pseudocyst. Giemsa stain, 40X.
Figure 1. A 5 mm erythematous papule with white scaling in 
the center
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recipients have found that the risk of T. gondii-
associated clinical disease ranges from 0 to 82% 
if patients receive organs from seropositive donors 
without antimicrobial prophylaxis (6,8).
Seronegative heart transplant patients should 
receive prophylaxis. Effective regimens include 
one single-strength co-trimoxazole tablet daily, 
one double-strength three times a week, 1,500 
mg atovaquone daily or pyrimethamine 25 mg/
day. This patient had received prophylaxis with co-
trimoxazole. Results from observational studies 
have shown that this drug is effective in preventing 
toxoplasmosis, even in cardiac recipients (6,11).
The patient may have developed severe disease 
despite co-trimoxazole prophylaxis due to resistance 
to sulfonamide (12,13). In this sense, more-virulent 
Toxoplasma strains have been found in Colombia 
and transmission of toxoplasmosis by renal trans-
plant was reported in two local cases (14,15). This 
suggests that the risk could be higher in tropical 
zones of the Americas where a high genetic diversity 
of Toxoplasma has been found. 
Co-trimoxazole is provided as a 1/5 ratio combi-
nation of trimethoprim and sulfamethoxazole. This 
ratio was chosen in order to provide synergistic 
ratio against bacteria, but due to the poor efficacy 
of trimethoprim against T. gondii trophozoites 
(100 times lower than pyrimethamine), the optimal 
ratio of the two compounds against this infection 
is probably closer to 1/1 (16). High doses of co-
trimoxazole are needed to cure experimental 
acute infection in mice, and relapses are observed 
after cessation of therapy, because it is ineffective 
on the cyst form of the parasite. However, it has 
proved remarkably efficient in the treatment and 
prophylaxis of toxoplasmosis in transplant patients 
with AIDS (11).
Considering that a high genetic diversity, gene 
polymorphisms in the dihydrofolate reductase and 
dihydropteroate synthase genes, more-virulent 
strains of T. gondii, and several transplanted 
patients with disseminated toxoplasmosis have 
been reported in Colombia, the recommended 
doses of co-trimoxazole could be insufficient, or 
another agent (e.g., dapsone plus pentamidine 
or pyrimethamine and sulfadiazine) could be 
necessary to prevent toxoplasmosis in high risk 
transplant patients.
It is also important to point out that this patient 
developed symptoms after eight months of trans-
plantation. Previous reports have described how 
heart transplant patients receiving the organ from 
seropositive donors usually develop infections four 
to twelve weeks after transplantation. According to 
previous reports, the organs most commonly affected 
by systemic toxoplasmosis in immunosuppressed 
patients are the lungs and the central nervous 
system (17,18).
To our knowledge, this is the first heart transplant 
patient reported in the literature presenting toxo-
plasmosis with cutaneous manifestations. Such 
cutaneous involvement is quite rare, and only a few 
cases have been reported in immunocompromised 
patients with great variability in the appearance of 
skin lesions. Generalized rash, erythema multiform-
like lesions, nodular lesions and vesicular varicella-
like lesions have been described (19-21). Skin 
biopsies confirmed the presence of the parasite, but 
histopathological findings are variable. The involve-
ment of the colon is also unique in this patient.
We can conclude, then, that diagnosing toxoplas-
mosis in immunosuppressed patients is challenging, 
as any organ may be affected. Thus, toxoplasmosis 
should always be suspected as a differential diag-
nosis in patients with systemic symptoms. Patients 
must be studied thoroughly, using all possible 
diagnostic aids to rule out the disease, including 
serology, histology, special immunohistochemical 
staining and PCR (22-23). Co-trimoxazole pro-
phylaxis does not exclude the diagnosis and 
resistance studies are necessary.
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